Cutaneous melanoma · line 1 · Pembrolizumab monotherapy (advanced/metastatic melanoma, 1L; KEYNOTE-006)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-PEMBRO-MONO-MELANOMA |
| ID | IND-MELANOMA-METASTATIC-1L-PEMBRO-MONO |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-30 | pending_clinical_signoff |
| Diseases | DIS-MELANOMA |
| Sources | SRC-ESMO-MELANOMA-2024 SRC-KEYNOTE-006-ROBERT-2015 SRC-NCCN-MELANOMA-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track 1L option for advanced / metastatic melanoma. Surfaced by curated case patient_melanoma_braf_wt_pembro_mono.json (KB drift note: indication did not exist; algorithm wiring to ALGO-MELANOMA-METASTATIC-1L is separate engine work). PD-L1-agnostic per KEYNOTE-006. Most relevant for irAE-frail BRAF-WT or BRAF-mut patients who prefer IO over targeted therapy. Pairs with adjuvant pembro indication (KEYNOTE-054).
Used By
Algorithms
ALGO-MELANOMA-METASTATIC-1L- ALGO-MELANOMA-METASTATIC-1L
Handbook Chapters
HB-MELANOMA-METASTATIC-1L- Metastatic melanoma: BRAF / IO first-line reasoning
Handbook Questions
HQ-MELANOMA-MET-1L-003- HQ-MELANOMA-MET-1L-003